Abstract
Background
The optimal radiotherapy regimen in elderly patients with glioblastoma treated by chemoradiation needs to be addressed. We provide the results of a comparison between conventionally fractionated standard radiotherapy (CRT) and short-course radiotherapy (SRT) in those patients treated by temozolomide-based chemoradiation.
Methods
Patients aged 65 years or older from the GBM-molRPA cohort were included. Patients who were planned for a ≥ 6-week or ≤ 4-week radiotherapy were regarded as being treated by CRT or SRT, respectively. The median RT dose in the CRT and SRT group was 60 Gy in 30 fractions and 45 Gy in 15 fractions, respectively.
Results
A total of 260 and 134 patients aged older than 65 and 70 years were identified, respectively. CRT- and SRT-based chemoradiation was applied for 192 (73.8%) and 68 (26.2%) patients, respectively. Compared to SRT, CRT significantly improved MS from 13.2 to 17.6 months and 13.3 to 16.4 months in patients older than 65 years (P < 0.001) and 70 years (P = 0.002), respectively. Statistical significance remained after adjusting for age, performance status, surgical extent, and MGMT promoter methylation in both age groups. The benefit was clear in all subgroup analyses for patients with Karnofsky performance score 70–100, Karnofsky performance score ≤ 60, gross total resection, biopsy, methylated MGMT promoter, and unmethylated MGMT promoter (all P < 0.05).
Conclusion
CRT significantly improved survival compared to SRT in elderly glioblastoma patients treated with chemoradiation in selected patients amenable for chemoradiation. This study is hypothesis-generating and a prospective randomized trial is urgently warranted.
Similar content being viewed by others
Change history
12 May 2020
The name of author Do Hoon Lim was incorrect in the initial online publication. The original article has been corrected.
Abbreviations
- GMB:
-
Glioblastoma
- TMZ:
-
Temozolomide
- RT:
-
Radiotherapy
- CRT:
-
Conventionally fractionated standard radiotherapy
- SRT:
-
Short-course radiotherapy
- MGMT :
-
O6-methylguanine-DNA methyltransferase
- GBM-molRPA:
-
Glioblastoma molecular recursive partitioning analysis
- GTR:
-
Gross total resection
- MS:
-
Median survival
References
Ostrom QT, Cioffi G, Gittleman H et al (2019) CBTRUS statistical report: primary Brain and other Central Nervous System Tumors diagnosed in the United States in 2012–2016. Neuro Oncol 21(5):51–5100
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
Wee CW, Kim E, Kim N et al (2017) Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. Radiother Oncol 123(1):106–111
Paszat L, Laperriere N, Groome P, Schulze K, Mackillop W, Holowaty E (2001) A population-based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51(1):100–107
Roa W, Brasher PM, Bauman G et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22(9):1583–1588
Keime-Guibert F, Chinot O, Taillandier L et al (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356(15):1527–1535
Malmström A, Grønberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13(9):916–926
Wick W, Platten M, Meisner C et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13(7):707–715
Roa W, Kepka L, Kumar N et al (2015) International Atomic Energy Agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 33(35):4145–4150
Minniti G, De Sanctis V, Muni R et al (2008) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 88(1):97–103
Minniti G, De Sanctis V, Muni R et al (2009) Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol 91(1):95–100
Brandes AA, Franceschi E, Tosoni A et al (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115(15):3512–3518
Minniti G, Lanzetta G, Scaringi C et al (2012) Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 83(1):93–99
Perry JR, Laperriere N, O'Callaghan CJ et al (2017) Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376(11):1027–1037
Arvold ND, Tanguturi SK, Aizer AA et al (2015) Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys 92(2):384–389
Cabrera AR, Kirkpatrick JP, Fiveash JB et al (2016) Radiation therapy for glioblastoma: executive summary of an American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol 6(4):217–225
Weller M, van den Bent M, Tonn JC et al (2017) European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 18(6):e315–e329
Kim YZ, Kim CY, Lim J et al (2019) The Korean Society for Neuro-oncology (KSNO) guideline for glioblastomas: version 2018.01. Brain Tumor Res Treat 7(1):1–9
National Comprehensive Cancer Network clinical practice guidelines in oncology. Central nervous system cancers, Version 3.2019. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed 26 Nov 2019.
Wee CW, Kim IH, Park CK et al (2018) Validation of a novel molecular RPA classification in glioblastoma (GBM-molRPA) treated with chemoradiation: a multi-institutional collaborative study. Radiother Oncol 129(2):347–351
Lim YJ, Kim IH, Han TJ et al (2015) Hypofractionated chemoradiotherapy with temozolomide as a treatment option for glioblastoma patients with poor prognostic features. Int J Clin Oncol 20(1):21–28
Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466
van den Bent MJ, Afra D, de Witte O et al (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366(9490):985–990
Best B, Nguyen HS, Doan NB et al (2019) Causes of death in glioblastoma: insights from the SEER database. J Neurosurg Sci 63(2):121–126
Jones B, Sanghera P (2007) Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma. Int J Radiat Oncol Biol Phys 68(2):441–448
Global Health Observatory data repository. https://apps.who.int/gho/data/view.main.60000?lang=en. Accessed 26 Nov 2019.
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that we have no conflict of interest.
Ethical approval
This study was approved by every institutional review boards of participating institutions (Seoul National University Hospital IRB No. 1804-144-941). For this type of study formal consent is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original version of this article has been revised: The seventh author’s name has been corrected.
Rights and permissions
About this article
Cite this article
Wee, C.W., Kim, I.H., Park, CK. et al. Chemoradiation in elderly patients with glioblastoma from the multi-institutional GBM-molRPA cohort: is short-course radiotherapy enough or is it a matter of selection?. J Neurooncol 148, 57–65 (2020). https://doi.org/10.1007/s11060-020-03468-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-020-03468-x